Vincristine, an efficacious alternative for diffuse neonatal haemangiomatosis.
Diffuse neonatal haemangiomatosis (DNH) is an uncommon condition characterized by multiple cutaneous and visceral haemangiomas frequently causing severe complications. Corticosteroids constitute the first therapeutic line; however, when they fail, other alternatives are available, provided possible side effects are closely monitored during and after treatment. We present a case of life-threatening DNH, non-responsive to corticosteroids, successfully treated with Vincristine with minor side effects. We conclude that Vincristine is a valid alternative in corticosteroid-resistant DNH.
Pérez-Valle
S
S
Servicio de Neonatología, Hospital Universitario Materno-Infantil La Fe, Valencia, Spain.
Peinador
M
M
Herraiz
P
P
Saénz
P
P
Montoliu
G
G
Vento
M
M
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D006391:Hemangioma / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007231:Infant, Newborn; D008099:Liver / Q000201:enzymology; D008113:Liver Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D008279:Magnetic Resonance Imaging; D008297:Male; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy*; D014750:Vincristine / Q000627:therapeutic use*
D000305:Adrenal Cortex Hormones; D000972:Antineoplastic Agents, Phytogenic; D014750:Vincristine